Lysophosphatidic Acid

By Targets:	Apoptosis (3) Autophagy (1) Biochemical Assay Reagents (1) Casein Kinase (2) DNA-PK (2) Endogenous Metabolite (1) Liposome (1) LPL Receptor (19) Phosphodiesterase (PDE) (4) PI3K (2) PPAR (1) ROCK (1) STAT (1) TRP Channel (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (4) Endocrinology (2) Infection (3) Inflammation/Immunology (9) Metabolic Disease (8) Neurological Disease (7)
Click Chemistry:	Alkynes (1)

Targets Recommended: Amino Acid Derivatives Hydroxycarboxylic Acid Receptor (HCAR) Free Fatty Acid Receptor Fatty Acid Synthase (FASN) Apical Sodium-Dependent Bile Acid Transporter G protein-coupled Bile Acid Receptor 1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-126967

*1-Palmitoyl lysophosphatidic* acid**	Endogenous Metabolite	Metabolic Disease
1-Palmitoyl lysophosphatidic acid is a lysophosphatidic acid that causes concentration-dependent aggregation of human platelets. 1-Palmitoyl lysophosphatidic acid causes changes in platelet shape, pseudopod development, and particle concentration. 1-Palmitoyl lysophosphatidic acid may induce platelet aggregation by stimulating the release of intracellular Ca .

HY-15706

H2L 5765834	LPL Receptor	Cardiovascular Disease
H2L 5765834 is an antagonist of lysophosphatidic acid receptors LPA₁, LPA₃, and LPA₅, with IC₅₀s of 94, 752, and 463 nM respectively .

HY-137862

*1-Oleoyl lysophosphatidic* acid** 1 Publications Verification 1-Oleoyl-sn-glycero-3-phosphate; 1-Oleoyl-LPA	LPL Receptor	Neurological Disease
1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) is an abundant lysophosphatidic acid (LPA) species with high biological activity due to its strong affinity for the LPA receptors. 1-Oleoyl lysophosphatidic acid is commonly used in most laboratories as a reagent for LPA receptor activation . 1-Oleoyl lysophosphatidic acid increases SRE-driven β-galactosidase activity .

HY-107614

*1-Oleoyl lysophosphatidic* acid sodium** 1 Publications Verification 1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium	LPL Receptor	Neurological Disease
1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) sodium, a potent bioactive phospholipid, is a LPA receptor activator. 1-Oleoyl lysophosphatidic acid sodium can promote mitosis by inducing DNA synthesis. 1-Oleoyl lysophosphatidic acid sodium is also involved in normal and pathological emotional responses, including anxiety and depression .

HY-160173

LPA receptor antagonist-1	LPL Receptor	Others
LPA receptor antagonist-1 (example 52) is an antagonist of lysophosphatidic acid (LPA) receptor. LPA receptor antagonist-1 can be used for kinds of studies .

HY-150204

ONO-0740556

LPL Receptor Inflammation/Immunology

ONO-0740556 is a potent Gi-coupled human lysophosphatidic acid receptor 1 (LPA1) agonist with an EC₅₀ value of 0.26 nM .

ONO-0740556	LPL Receptor	Inflammation/Immunology
ONO-0740556 is a potent Gi-coupled human lysophosphatidic acid receptor 1 (LPA1) agonist with an EC₅₀ value of 0.26 nM .

HY-160003

PPARγ agonist 9	PPAR	Metabolic Disease
PPARγ agonist 9 is an agonist of PPARγ. PPARγ agonist 9 is the analogue of lysophosphatidic acid with an EC₅₀ more than 10 μM for LPA₃ receptor .

HY-107501

*(Rac)-1-Oleoyl lysophosphatidic* acid sodium** (Rac)-1-Oleoyl-sn-glycero-3-phosphate sodium; (Rac)-1-Oleoyl-LPA sodium	Others	Neurological Disease
(Rac)-1-Oleoyl lysophosphatidic acid ((Rac)-1-Oleoyl-sn-glycero-3-phosphate) sodium is the racemic isomer of 1-Oleoyl lysophosphatidic acid sodium (HY-107614) .

HY-N12840

Logmalicid B

Others Metabolic Disease

Logmalicid B is an iridoid glycoside compound that can be isolated from Cornus officinalis and can be used in diabetes research .

Logmalicid B	Others	Metabolic Disease
Logmalicid B is an iridoid glycoside compound that can be isolated from Cornus officinalis and can be used in diabetes research .

HY-109854A

(R)-Lisofylline (R)-Lisophylline	STAT	Metabolic Disease Inflammation/Immunology
(R)-Lisofylline ((R)-Lisophylline) is a (R)-enantiomer of the metabolite of Pentoxifylline with anti-inflammatory properties. (R)-Lisofylline is a lysophosphatidic acid acyltransferase inhibitor with an IC₅₀ of 0.6 µM and interrupts IL-12 signaling-mediated STAT4 activation. (R)-Lisofylline has the potential for type 1 diabetes, autoimmune disorders research .

HY-115450

ONO-0300302	LPL Receptor	Endocrinology Cancer
ONO-0300302 is an orally active and potent LPA1 (lysophosphatidic acid receptor 1) antagonist, with an IC₅₀ of 0.086 μM. ONO-0300302 is a slow tight binding inhibitor, and its binding affinity increases with time, with K_d of 0.34 nM (37 °C, 2 h). ONO-0300302 can be used for benign prostatic hyperplasia (BPH) research .

HY-116100A

HA155

Phosphodiesterase (PDE) Inflammation/Immunology

HA-155 is a potent and selective autotaxin (ATX) inhibitor with an IC₅₀ of 5.7 nM .

HA155	Phosphodiesterase (PDE)	Inflammation/Immunology
HA-155 is a potent and selective autotaxin (ATX) inhibitor with an IC₅₀ of 5.7 nM .

HY-12812

Autotaxin modulator 1	Phosphodiesterase (PDE)	Neurological Disease Cancer
Autotaxin modulator 1 is an autotaxin (ATX) enzyme inhibitor, extracted from patent WO 2014018881 A1, Compound Example 12b. Autotaxin modulator 1 is expected to be useful for researching demyelination due to injury or disease, as well as for researching proliferative disorders such as cancer .

HY-128127

NAEPA

LPL Receptor Others

NAEPA, a phosphate-mimetic derivative, is a lysophosphatidic acid (LPA) receptor agonist .

NAEPA	LPL Receptor	Others
NAEPA, a phosphate-mimetic derivative, is a lysophosphatidic acid (LPA) receptor agonist .

HY-W127502

1-Hexadecylglycero-3-phosphate 1-Hex-GPA	Biochemical Assay Reagents	Others
1-Hexadecyl lysophosphatidic acid is an ether analog of lysophosphatidic acid (LPA) containing a hexadecyl group in the sn-1 position. LPA binds to five different G protein-coupled receptors and mediates a variety of biological responses, including cell proliferation, smooth muscle contraction, platelet aggregation, neurite contraction, and cell motility.

HY-100882

ONO-7300243

LPL Receptor Cardiovascular Disease

ONO-7300243 is a novel, potent lysophosphatidic acid receptor 1 (LPA1) antagonist with IC₅₀ of 0.16 μM.
HY-107616

H2L5186303

LPL Receptor Others

H2L5186303 is a potent and selective LPA ² receptor (lysophosphatidic acid 2 receptor) antagonist with an IC₅₀ of 9 nM .

ONO-7300243	LPL Receptor	Cardiovascular Disease
ONO-7300243 is a novel, potent lysophosphatidic acid receptor 1 (LPA1) antagonist with IC₅₀ of 0.16 μM.

H2L5186303	LPL Receptor	Others
H2L5186303 is a potent and selective LPA ² receptor (lysophosphatidic acid 2 receptor) antagonist with an IC₅₀ of 9 nM .

HY-18076

LPA1 receptor antagonist 1	LPL Receptor	Infection Inflammation/Immunology
LPA1 receptor antagonist 1 is a highly selective Lysophosphatidic Acid receptor-1 (LPA1) antagonist with an IC₅₀ of 25 nM.

HY-117444

ONO-9780307

LPL Receptor Cancer

ONO-9780307 is a specific synthetic LPA1 (lysophosphatidic acid receptor 1) antagonist with an IC₅₀ value of 2.7 nM .

ONO-9780307	LPL Receptor	Cancer
ONO-9780307 is a specific synthetic LPA1 (lysophosphatidic acid receptor 1) antagonist with an IC₅₀ value of 2.7 nM .

HY-126233

PAT-347	Phosphodiesterase (PDE)	Metabolic Disease
PAT-347 is an Autotaxin (ATX) inhibitor. ATX is a secretory enzyme that hydrolyzes lysophosphatidylcholine (LPC) and regulates lysophosphatidic acid (LPA) production in the blood .

HY-114380

Radioprotectin-1	LPL Receptor	Others
Radioprotectin-1 is a potent and specific nonlipid agonist of lysophosphatidic acid receptor 2 (LPA₂), with an EC₅₀ value of 25 nM for murine LPA₂ subtype .

HY-120478

ASP6432	LPL Receptor	Infection
ASP6432 is a potent and selective *type 1 lysophosphatidic* acid receptor (LPA1) antagonist with IC₅₀**s of 11 nM and 30 nM for human LPA1 and rat LPA1, respectively .

HY-125854

Phosphatidylcholines, egg	Liposome	Metabolic Disease
Phosphatidylcholines, egg is an important part of eukaryotic membranes. Phosphatidylcholines, egg is also a major source of the second messenger Diacylglycerol, Phosphatidic acid, Lysophosphatidic acid, and Arachidonic acid, which can be further metabolized to other signaling molecules .

HY-160616

LPA5 antagonist 3	LPL Receptor	Cardiovascular Disease Neurological Disease
LPA5 antagonist 3 (Example 74) is a lysophosphatidic acid receptor 5 (LPA5) antagonist, with an IC₅₀ of 170 nM. LPA5 antagonist 3 can be used for the research of pain disorders and atherosclerosis .

HY-114379

AS2717638 1 Publications Verification	LPL Receptor	Inflammation/Immunology
AS2717638 is an oral active and selective lysophosphatidic acid receptor 5 (LPA5) antagonist, with an IC₅₀ of 38 nM for hLPA5. AS2717638 also significantly improves PGE₂-, PGF_2α-, and AMPA-induced allodynia .

HY-151392

LPA5 antagonist 2	Others	Neurological Disease Inflammation/Immunology
LPA5 antagonist 2 (compound 65) is a high aqueous solubility LPA5 (lysophosphatidic acid receptor 5) antagonist. LPA5 antagonist 2 significantly attenuates nociceptive hypersensitivity and it can be used for the research of inflammatory and neuropathic pains .

HY-157639A

18:2 Lyso PA sodium	Others	Cardiovascular Disease
18:2 Lyso PA sodium is an unsaturated lysophosphatidic acid (LysoPA), a lipid mediator mainly present in plasma and thought to be involved in the pathogenesis of acute coronary syndrome (ACS). 18:2 Lyso PA sodium significantly correlates with serum autotaxin (ATX) in peripheral arteries .

HY-139853

BMS-986278	LPL Receptor	Others
BMS-986278 is a potent and orally active lysophosphatidic acid receptor 1 (LPA1) antagonist, with K_bs of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively. BMS-986278 can be used for the research of pulmonary fibrotic diseases .

HY-132222

SET2	TRP Channel	Cancer
SET2 is a selective TRPV2 antagonist (IC₅₀=0.46 μM). SET2 blocks the TRP channel and suppresses prostate cancer cells migration. SET2 reduces the lysophosphatidic acid (LPA, a TRPV2 activator)-induced cytoplasmic calcium increases .

HY-117779

DBIBB	Apoptosis	Endocrinology
DBIBB is a specific nonlipid agonist of the type 2 G protein coupled receptor for lysophosphatidic acid (LPA2). DBIBB mitigates the gastrointestinal radiation syndrome, increases intestinal crypt survival and enterocyte proliferation, and reduces apoptosis. DBIBB represents a agent candidate capable of mitigating acute radiation syndrome caused by high-dose γ-radiation to the hematopoietic and gastrointestinal system .

HY-123522

PAT-048	Phosphodiesterase (PDE)	Inflammation/Immunology
PAT-048 is a potent, selective and orally active autotaxin inhibitor, inhibits IL-6 mRNA expression, but shows no effect on autotaxin protein and pulmonary lysophosphatidic acid (LPA) production in lung fibrosis model. PAT-048 shows an IC₅₀ and IC₉₀ of 20 nM and 200 nM for autotaxin in mouse plasma. PAT-048 reduces dermal fibrosis in vivo .

HY-10108

LY294002 Maximum Cited Publications 708 Publications Verification	PI3K Casein Kinase DNA-PK Apoptosis Autophagy	Infection Cancer
LY294002 is a broad-spectrum inhibitor of PI3K with IC₅₀s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively . LY294002 also inhibits CK2 with an IC₅₀ of 98 nM . LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC₅₀ of 1.4 μM. LY294002 is an apoptosis activator .

HY-100619A

BMS-986020 sodium 4 Publications Verification AM152 sodium	LPL Receptor	Metabolic Disease Inflammation/Immunology
BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC₅₀s of 4.8 µM, 6.2 µM, and 7.5 µM for BSEP, MRP4, and MDR3, respectively . BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .

HY-100619

BMS-986020 4 Publications Verification AM152	LPL Receptor	Metabolic Disease Inflammation/Immunology
BMS-986020 (AM152) is a high-affinity and selective lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 inhibits bile acid and phospholipid transporters with IC₅₀s of 4.8 µM, 6.2 µM, and 7.5 µM for BSEP, MRP4, and MDR3, respectively . BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .

HY-139061

Palmitoyl 3-carbacyclic phosphatidic acid	LPL Receptor ROCK	Cancer
Palmitoyl 3-carbacyclic phosphatidic acid (HY-139061) is a palmitoylated Carba-like cyclophosphatidic acid and an analog of lysophosphatidic acid (LPA). Palmitoyl 3-carbacyclic phosphatidic acid has different functions from LPA and can inhibit the activation of RhoA and inhibit the migration of melanoma cells. Palmitoyl 3-carbacyclic phosphatidic acid effectively inhibited experimental lung metastasis and reduced the number of tumor nodules in a B16-F0 xenograft mouse model .

HY-10108A

LY294002 hydrochloride	PI3K Casein Kinase DNA-PK Apoptosis	Cancer
LY294002 hydrochloride is a potent and broad-spectrum PI3K inhibitor, with IC₅₀ values of 0.5, 0.57, and 0.97 μM for P110α, P110δ and P110β, respectively. LY294002 hydrochloride also inhibits CK2 with an IC₅₀ of 98 nM. LY294002 hydrochloride can be used for pancreatic cancer research .

Cat. No.	Product Name	Type

HY-W127502

1-Hexadecylglycero-3-phosphate 1-Hex-GPA	Cell Assay Reagents
1-Hexadecyl lysophosphatidic acid is an ether analog of lysophosphatidic acid (LPA) containing a hexadecyl group in the sn-1 position. LPA binds to five different G protein-coupled receptors and mediates a variety of biological responses, including cell proliferation, smooth muscle contraction, platelet aggregation, neurite contraction, and cell motility.

Cat. No.	Product Name	Target	Research Area

HY-P0103

Myristoyl pentapeptide-17	Peptides	Others
Myristoyl pentapeptide-17 can stimulate eyelash growth by stimulating keratin production. Myristoyl pentapeptide-17 promotes the delivery of key ingredients in the serum, such as the growth factors and lysophosphatidic acid .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-126967

*1-Palmitoyl lysophosphatidic* acid**	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
1-Palmitoyl lysophosphatidic acid is a lysophosphatidic acid that causes concentration-dependent aggregation of human platelets. 1-Palmitoyl lysophosphatidic acid causes changes in platelet shape, pseudopod development, and particle concentration. 1-Palmitoyl lysophosphatidic acid may induce platelet aggregation by stimulating the release of intracellular Ca .

HY-N12840

Logmalicid B	Structural Classification Iridoids Cornaceae Cornus officinalis Sieb. et Zucc. Terpenoids Source classification Plants	Others
Logmalicid B is an iridoid glycoside compound that can be isolated from Cornus officinalis and can be used in diabetes research .

Cat. No.	Compare	Product Name	Species	Source

HY-P702209

	AGPAT4 Protein, Human (Cell-Free, His) 1-acylglycerol-3-phosphate O-acyltransferase 4; 1-AGP acyltransferase 4; 1-AGPAT 4; Lysophosphatidic Acid acyltransferase delta; LPAAT-delta	Human	E. coli Cell-free
	The AGPAT4 protein plays a role in lipid metabolism by converting 1-acyl-sn-glycerol-3-phosphate (lysophosphatidic acid or LPA) into 1,2-diacyl-sn-glycerol-3-phosphate (phosphatidic acid or PA) play a vital role. An acyl moiety is incorporated (by similarity) at the sn-2 position of the glycerol backbone. AGPAT4 Protein, Human (Cell-Free, His) is the recombinant human-derived AGPAT4 protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of AGPAT4 Protein, Human (Cell-Free, His) is 319 a.a., with molecular weight of 45.5 kDa.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83630

EDG2 Antibody (YA3375)

Lysophosphatidic Acid receptor 1; LPA receptor 1; LPA-1; Lysophosphatidic Acid receptor Edg-2; LPAR1; EDG2; LPA1
WB, IHC-P, IP Human

Cat. No.	Product Name		Classification

HY-151391

LPA5 antagonist 1		Alkynes
LPA5 antagonist 1 (Compound 66) is a potent and selective lysophosphatidic acid receptor 5 (LPA5) antagonist (IC₅₀=32 nM). LPA5 antagonist 1 shows high brain permeability and anti-nociceptive activity. LPA5 antagonist 1 can be used in inflammatory and neuropathic pain research . LPA5 antagonist 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Click Chemistry

Lysophosphatidic Acid

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Antibodies

Click Chemistry

Natural
Products